Incentive Programs
Neola Medical has the following outstanding incentive programs:
Employee Stock Option Program 2026/2029:1
(for employees, excluding the CEO), resolved by the Annual General Meeting on May 28, 2026. The program comprises a maximum of 3,000,000 employee stock options. Each option entitles the holder to acquire one share in Neola Medical. The options vest on July 1, 2029 and may be exercised during the period July 1–September 30, 2029.
Employee Stock Option Program 2026/2029:2
(for Board members), resolved by the Annual General Meeting on May 28, 2026. The program comprises a maximum of 3,000,000 employee stock options. Each option entitles the holder to acquire one share in Neola Medical. The options vest on July 1, 2029 and may be exercised during the period July 1–September 30, 2029.
Employee Stock Option Program 2026/2032:1
(for the CEO), resolved by the Annual General Meeting on May 28, 2026. The program comprises a maximum of 6,000,000 employee stock options, allocated across four vesting years from 2029 to 2032.
Employee Stock Option Program 2026/2029:2
(for Board members), resolved by the Annual General Meeting on May 28, 2026. The program comprises a maximum of 3,000,000 employee stock options. Each option entitles the holder to acquire one share in Neola Medical. The options vest on July 1, 2029 and may be exercised during the period July 1–September 30, 2029.
LTI 2022/2026
(for chief executive officer) that was decided at the Extra General Meeting on September 27, 2022. The incentive programme will run for a period of four full financial years, i.e. from January 1 to December 31, during 2022 – 2025.
Warrants 2023/2027A
(for senior executives, other employees and consultants in the Company) that was decided at the Annual General Meeting on May 17, 2023. During the exercise period, which runs from and including 1 June 2027 to and including 30 June 2027, these may be used for subscription of newly issued shares in the Company.
Warrants 2023/2027B
(for board members) that was decided at the Annual General Meeting on May 17, 2023. During the exercise period, which runs from and including 1 June 2027 to and including 30 June 2027, these may be used for subscription of newly issued shares in the Company.
Right Issues
Reports and Financial Calendar
